Primary Analysis Results From Novartis Pivotal JULIET Trial Show Kymriah(TM) (Tisagenlecleucel) Sustained Complete Responses at Six Months in Adults With R/r DLBCL, a Difficult-to-Treat Cancer
December 10, 2017
December 10, 2017
BASEL, Switzerland, Dec. 10 -- Novartis issued the following news release:
Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with KymriahTM (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The data from this pivotal trial, led by researchers from the University of Pennsylvania (Penn), show an overall response rate . . .
Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with KymriahTM (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The data from this pivotal trial, led by researchers from the University of Pennsylvania (Penn), show an overall response rate . . .